Martin R. Jefson

Foley & Lardner LLP engages in the provision of legal services. Its practice areas include employee benefits and executive compensation, environmental, estates and trusts, finance, international tax and transfer pricing, private equity and venture capital, real estate, securities, commodities and exchange regulation, taxation, and transactions. The company was founded by Asahel Finch and William Pitt Lynde on September 8, 1842 and is headquartered in Milwaukee, WI.

Zielbio, Inc. develops a technology for identification of cancerous diseases. Its technology identifies high-value biomarkers of disease as well as companion targeting peptides capable of delivery of therapeutic payloads and as imaging agents. The company was founded by Kimberly A. Kelly, Gregory B. Fralish, Todd William Bauer in 2010 and is headquartered in Charlottesville, VA.

2020, Inc. offers eye care services. It also offers delivers on-site eye care and eye exams to businesses and their employees via a mobile eye clinic. The company was founded by Howard Bornstein in 2013 and is headquartered in Boston, MA.

Cancer Targeting Systems, Inc. offers cancer care. The firm focuses on delivering cancer theranostic products combining imaging with therapy. The company was founded by Martin Pomper and Will West and is headquartered in Boston, MA.

Puretech Health LLC (PureTech Ventures) is a venture capital subsidiary of PureTech Health Plc founded in 2000 by Daphne Zohar, Robert Langer and Ben Shapiro. The firm is headquartered in Boston, Massachusetts.

Morningside Group (Morningside Group) is a venture capital and private equity firm founded in 1986 by Lok Chung Chan and Chi Chung Chan. The firm is headquartered in Hong Kong.

New Leaf Venture Partners LLC (New Leaf Ventures) is an independent Venture Capital firm founded by Jeani Delagardelle, Philippe Chambon, Vijay Lathi, Ron Hunt, James Niedel, and Kathy LaPorte. The firm is headquartered in New York. It spun out from Sprout Group.

Part of Pfizer Inc., Pfizer (St. Louis) is a company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO.

CellCentric Ltd. develops and commercializes small molecule inhibitors for cancer. Its active programs include inhibitors to histone methyltransferases, histone demethylases and epigenetic enzymes that act via ubiquitin. The company was founded by Alun Huw Jones, Catherine Denise Prescott, Azim Surani and William Henry Lewarne West in May 2004 and is headquartered in Cambridge, the United Kingdom.

GreenLight Biosciences, Inc. engages in a biotechnology company.. It delivers attractive solution for production of chemicals and fuels from renewable resources, eliminating the need for petroleum feedstocks. The company was founded by Andrey J. Zarur, Marta Ortega-Valle, and James R. Swartz and is headquartered in Medford, MA.

Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France.

Vigeo Therapeutics, Inc. manufactures cancer drugs. It develops therapies designed to reprogram the tumor immune microenvironment by targeting CD36 and CD47 via Tsp-1 induction. The company was founded by Randolph Watnick and Jing Watnick in 2011 and is headquartered in Cambridge, MA.

ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France.

Astrocyte Pharmaceuticals, Inc. operates as a drug development company. The firm focuses on neuroprotective strategy to protect and repair neurons that are damaged by selectively stimulating astrocytes. The company was founded by William S. Korinek and James D. Lechleiter in 2014 and is headquartered in Cambridge, MA.

Alms Therapeutics SAS provides research and development in the treatment of diabetes. The company was founded by Jason Robert Dinges on July 4, 2017 and is headquartered in Paris, France.

Apic Bio, Inc. engages in the development of treatment for neurological and liver diseases. It offers THRIVE, a platform that silences a mutant gene product and replaces a normal gene product in a single dual function vector. The company was founded by Robert H. Brown, Jr., John Reilly, and Christian Mueller in 2017 and is headquartered in North Cambridge, MA.

Allysta Pharmaceuticals, Inc. operates as a biopharmaceutical company. The frim develops medicine for ophthalmology, particularly dry eye disease and glaucoma. The company was founded by Henry H. Hsu and is headquartered in San Mateo, CA.

Alentis Therapeutics AG develops novel medications to treat advanced liver diseases and cancers. The company was founded by Neil Goldsmith on March 1, 2019 and is headquartered in Basel, Switzerland.

Prilenia Therapeutics BV develops and manufactures pharmaceuticals. The company was founded in 2018 and is headquartered in Naarden, the Netherlands.

Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million.

Adiso Therapeutics, Inc. creates medicines to treat inflammatory diseases with the goal of improving the lives of patients and their families. Adiso Therapeutics is based in Concord, MA. The company believes that current therapeutic approaches are often inadequate and can pose significant safety concerns for patients. Scott T. Megaffin has been the CEO of the company since 2022.

NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands.

Provectra Therapeutics, Inc. manufactures pharmaceutical products. The private company is based in Chapel Hill, NC. The company was founded by Larry Douglas Altstiel.